Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Veröffentlicht am September 22
These companies are pioneering breakthrough technologies like robotic surgery and AI-powered diagnostics that are revolutionising healthcare. As medical technology advances, early investors could benefit from the massive market potential.
With ageing populations worldwide and rising healthcare spending, these medical technology leaders are positioned to capture growing demand. The sector offers defensive growth that's less sensitive to economic downturns.
These aren't speculative bets but established industry giants with decades of innovation and consistent profitability. Many pay dividends whilst continuing to invest heavily in research and development.
This group captures the long-term growth potential of global healthcare technology, driven by ageing populations, rising chronic disease rates, and continuous medical innovation. By focusing on established leaders in robotic surgery, diagnostic imaging, and medical devices, we're targeting companies at the forefront of life-saving technological advancement.
These are defensive, high-growth companies that benefit from consistent healthcare demand regardless of economic cycles. The group includes both innovative technology pioneers and established medical device conglomerates, providing a balanced mix of growth potential and stability in a sector that's essential to human wellbeing.
Each company was selected for its leadership position in the global medical technology supply chain. From robotic surgery innovators to diagnostic imaging giants, these firms dominate their respective niches and are well-positioned to benefit from the relentless pace of healthcare innovation and growing global medical device demand.
Market cap breakdown for a medtech-focused basket with total market cap and constituent market caps provided.
JNJ: $462.30B
ABT: $221.98B
MDT: $122.91B
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Here are a few of the assets in this group. Create an account to unlock the full list.
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 17.74 % zulegen.
6 von 8 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+17.74%
